The clinical problem the team set out to address is well known in urologic oncology. Current risk stratification for clear cell renal cell carcinoma relies heavily on the TNM staging system, which grades tumors by size, lymph node involvement, and metastatic spread. That framework leaves many patients poorly sorted, and it offers limited guidance for one of the field’s most consequential decisions: whether to prescribe adjuvant targeted therapy after nephrectomy. Existing evidence suggests that such therapy delivers a survival benefit of only about 5.4 to 10.5 percent, meaning many patients endure toxic treatment with little gain while others who might benefit go untreated. A tool that could identify who falls into which group would represent a genuine advance in precision oncology.

The researchers built their model from two cohorts of patients with resectable clear cell renal cell carcinoma who had undergone preoperative contrast-enhanced CT and exome sequencing. The training cohort comprised 226 patients treated at Xijing Hospital, while an independent testing cohort of 134 patients was drawn from public repositories, The Cancer Imaging Archive and The Cancer Genome Atlas. Using the open-source platforms 3D Slicer and PyRadiomics, the team extracted hundreds of quantitative radiomic features from two distinct regions of interest on each scan: the tumor itself and the perirenal fat enveloping the kidney.

Radiomics, the technique at the heart of the study, converts the subtle gray-scale textures of medical images into numbers. Features such as texture heterogeneity, shape descriptors, and intensity statistics capture biological properties that the human eye cannot reliably perceive, including tumor cellularity, necrosis, and vascular architecture. What makes this study distinctive is its insistence that the perirenal fat deserves equal billing. Previous work has linked both the volume and the density of this fat compartment to clear cell renal cell carcinoma outcomes, plausibly because fat tissue is not a passive bystander but an active endocrine organ that secretes inflammatory and metabolic signals capable of shaping tumor behavior. Until now, however, fat features had not been systematically integrated with tumor radiomics and genomics in a single prognostic framework.

To distill the high-dimensional feature sets into usable scores, the researchers applied least absolute shrinkage and selection operator regression, a technique that prunes redundant variables while preserving the most informative ones, followed by stepwise Cox regression to build the final radiomic scores for tumor and fat. In parallel, they constructed a genetic score from sequencing data covering 639 cancer-related genes, focusing on the twenty most frequently mutated genes, and a clinical score anchored in conventional variables such as TNM stage. The three strands were then woven into a multimodal nomogram, a visual calculation tool that clinicians can use at the bedside to estimate an individual patient’s probability of remaining progression-free.

The performance figures are striking. The combined nomogram achieved a concordance index of 0.856 in the training cohort and 0.859 in the testing cohort, comfortably outperforming each unimodal score on its own. Time-dependent area under the curve values for one-to-five-year progression-free survival were consistently higher for the integrated model than for any single data stream. A concordance index approaching 0.86 indicates that, for roughly 86 percent of comparable patient pairs, the model correctly ranks which patient will progress first, a level of discrimination that approaches the accuracy of well-established clinical prediction tools in other cancer types.

To open the black box of their model, the team turned to SHAP analysis, a game-theoretic method that quantifies each input’s contribution to individual predictions. The analysis identified the tumor radiomic score, the perirenal fat score, TP53 mutation status, and grade G4 histology as the key drivers of the model’s output. That TP53, one of the most famous tumor suppressor genes in all of cancer biology, emerged alongside imaging features underscores the logic of the radiogenomic approach: the model does not merely correlate images with outcomes, it triangulates across scales, linking what the scanner sees with what the sequencer reads and what the pathologist grades.

The researchers went further, deploying multiple machine learning algorithms, including random forest, support vector machine, gradient boosting decision tree, K-nearest neighbors, logistic regression, and naive Bayes classifiers, to predict four genes with independent prognostic value, then examining how those genes correlate across the multimodal dataset. Subgroup analyses confirmed that the model’s risk stratification remained robust when patients were partitioned by clinical characteristics. In other words, the tool did not simply perform well on average; it maintained its discriminatory power across the heterogeneous patient population that clinicians actually encounter.

Perhaps the most clinically provocative finding concerns adjuvant targeted therapy, which in this context refers primarily to vascular endothelial growth factor receptor tyrosine kinase inhibitors. The team calculated a risk difference rate for each patient and found a clear divide. Patients whose predicted risk difference reached 47 percent or higher lived longer with targeted therapy, showing a hazard ratio of 0.545 for progression, statistically significant at p equals 0.038. Patients whose risk difference fell below 10 percent fared better without the drugs, with a hazard ratio of 2.051 at p equals 0.035, meaning the therapy was associated with worse outcomes in that low-benefit group. Similar trends appeared within high-risk subgroups. The authors are careful to label these therapy-related analyses exploratory, and they emphasize that prospective validation is required before any change to clinical practice, but the directional signal is exactly what a precision oncology tool promises: the right drug for the right patient, and no drug for those who would only absorb its toxicity.

The study’s limitations are those of its design. It is retrospective, drawing on patients who were already treated, and the testing cohort, though independent, comes from public archives rather than a prospective multicenter trial. The therapy findings in particular rest on subgroup comparisons that could be confounded by unmeasured variables. Still, the conceptual contribution is substantial. By demonstrating that perirenal fat features carry prognostic weight on par with tumor genetics, the Xi’an team has broadened the canvas of radiogenomics and offered a template for integrating imaging, sequencing, and clinical data without requiring any test beyond a standard contrast-enhanced CT that most surgical patients already receive. If prospective studies confirm the model’s performance, the fat around the kidney may become one of the most informative tissues in renal cancer medicine, and the era of guessing who benefits from adjuvant therapy may give way to an era of calculating it.

Subject of Research: A CT-based multimodal radiogenomic model integrating tumor and perirenal fat radiomic features with genomic and clinical data for prognosis and adjuvant therapy selection in clear cell renal cell carcinoma.

Article Title: CT-based multimodal radiogenomic model integrating tumor and perirenal fat features for prognosis in clear cell renal cell carcinoma

Article References: Zhang, Y.-F., Ji, Y.-H., Wen, D.-D., Liu, C., Shi, P.-W., Hou, H.-Z., Quan, P.-H., Fan, X.-Z., Yang, B., Yao, Z., Guo, J.-M., Lu, X.-M., Yang, X.-J., Zheng, M.-W., & Zhang, L.-L. (2026). CT-based multimodal radiogenomic model integrating tumor and perirenal fat features for prognosis in clear cell renal cell carcinoma. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02920-0

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02920-0

Keywords: clear cell renal cell carcinoma, radiogenomics, radiomics, perirenal fat, CT imaging, nomogram, prognosis, targeted therapy, machine learning, TP53, progression-free survival, precision oncology